| Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals LS Gasbjerg, MM Helsted, B Hartmann, MH Jensen, MBN Gabe, ... Diabetes 68 (5), 906-917, 2019 | 142 | 2019 |
| Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice H Kissow, B Hartmann, JJ Holst, NE Viby, LS Hansen, MM Rosenkilde, ... Regulatory peptides 179 (1-3), 91-100, 2012 | 108 | 2012 |
| The gluco-and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor M Asmar, A Asmar, L Simonsen, LS Gasbjerg, AH Sparre-Ulrich, ... Diabetes 66 (9), 2363-2371, 2017 | 104 | 2017 |
| Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ... Diabetologia 62, 665-675, 2019 | 99 | 2019 |
| Species‐specific action of (Pro3) GIP–A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors AH Sparre‐Ulrich, LS Hansen, B Svendsen, M Christensen, FK Knop, ... British journal of pharmacology 173 (1), 27-38, 2016 | 93 | 2016 |
| N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor LS Hansen, AH Sparre‐Ulrich, M Christensen, FK Knop, B Hartmann, ... British journal of pharmacology 173 (5), 826-838, 2016 | 88 | 2016 |
| GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study LS Gasbjerg, MB Christensen, B Hartmann, AR Lanng, AH Sparre-Ulrich, ... Diabetologia 61, 413-423, 2018 | 82 | 2018 |
| Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists LS Gasbjerg, NC Bergmann, S Stensen, MB Christensen, MM Rosenkilde, ... Peptides 125, 170183, 2020 | 81 | 2020 |
| Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7 A Steen, S Thiele, D Guo, LS Hansen, TM Frimurer, MM Rosenkilde Journal of Biological Chemistry 288 (18), 12511-12521, 2013 | 75 | 2013 |
| Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents LS Gasbjerg, MBN Gabe, B Hartmann, MB Christensen, FK Knop, JJ Holst, ... Peptides 100, 173-181, 2018 | 71 | 2018 |
| Human GIP (3-30) NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not … MBN Gabe, AH Sparre-Ulrich, MF Pedersen, LS Gasbjerg, A Inoue, ... Biochemical pharmacology 150, 97-107, 2018 | 69 | 2018 |
| GIP (3–30) NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release AH Sparre-Ulrich, MN Gabe, LS Gasbjerg, CB Christiansen, B Svendsen, ... Biochemical pharmacology 131, 78-88, 2017 | 66 | 2017 |
| The role of incretins on insulin function and glucose homeostasis JJ Holst, LS Gasbjerg, MM Rosenkilde Endocrinology 162 (7), bqab065, 2021 | 65 | 2021 |
| GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men K Skov-Jeppesen, MS Svane, C Martinussen, MBN Gabe, LS Gasbjerg, ... Bone 125, 178-185, 2019 | 50 | 2019 |
| No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon … NC Bergmann, LS Gasbjerg, SM Heimbürger, LSL Krogh, F Dela, ... Diabetes Care 43 (3), 588-596, 2020 | 46 | 2020 |
| GLP-1 and GIP receptor signaling in beta cells–a review of receptor interactions and co-stimulation A Mayendraraj, MM Rosenkilde, LS Gasbjerg Peptides 151, 170749, 2022 | 45 | 2022 |
| GIP and GLP-1 receptor antagonism during a meal in healthy individuals LS Gasbjerg, MM Helsted, B Hartmann, AH Sparre-Ulrich, S Veedfald, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), e725-e738, 2020 | 45 | 2020 |
| Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes NC Bergmann, A Lund, LS Gasbjerg, NR Jørgensen, L Jessen, ... The Journal of Clinical Endocrinology & Metabolism 104 (7), 2953-2960, 2019 | 45 | 2019 |
| Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients with ST-elevation myocardial infarction: a randomized placebo controlled trial S Ekeloef, N Halladin, S Fonnes, SE Jensen, T Zaremba, J Rosenberg, ... Journal of cardiovascular translational research 10, 470-479, 2017 | 43 | 2017 |
| The bile acid‐sequestering resin sevelamer eliminates the acute GLP‐1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes A Brønden, A Albér, U Rohde, LS Gasbjerg, JF Rehfeld, JJ Holst, ... Diabetes, Obesity and Metabolism 20 (2), 362-369, 2018 | 40 | 2018 |
